Meta-analysis of nebulized amphotericin B to prevent or treat pulmonary aspergillosis in immunosuppressed animals

Transplant Infectious Disease

Volumn 10, Issue 3, 2008, Pages 168-176

  Ho, K M ^a   Duff, O ^a   Chambers, D ^a   Murray, R ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Amphotericin; Aspergillus; Immunocompromised state; Invasive fungal infection; Prevention

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CYCLOPHOSPHAMIDE; LUNG SURFACTANT; PLACEBO; STEROID;

ARTICLE; ASPERGILLUS FUMIGATUS; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DATA BASE; DATA EXTRACTION; DRUG EFFICACY; EMBASE; IMMUNOCOMPROMISED PATIENT; INFORMATION RETRIEVAL; LUNG ASPERGILLOSIS; MEDLINE; MORBIDITY; MORTALITY; NEBULIZATION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; IMMUNOSUPPRESSION; LUNG DISEASES, FUNGAL;

EID: 43949127090     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2007.00290.x     Document Type: Article

References (29)

1. Rapp RP. Changing strategies for the management of invasive fungal infections. Pharmacotherapy 2004 24 (Part 2) : 4S 28S.
2. Mohammad RA, Klein KC. Inhaled Amphotericin B for prophylaxis against invasive Aspergillus infections. Ann Pharmacother 2006 40 : 2148 2154.
3. Husain S, Zaldonis D, Kusne S, Kwak EJ, Paterson DL, McCurry KR. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis 2006 8 : 213 218.
4. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006 91 : 1068 1075.
5. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002 347 : 408 415.
6. Garbino J, Schnetzler G, Roberts C. Invasive aspergillosi: is treatment with "inexpensive" amphotericin B cost saving if "expensive" voriconazole is only used on demand? Swiss Med Wkly 2006 136 : 624 630.
7. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001 322 : 579 582.
8. Wingard JR, Leather HL, Wood CA, et al. Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. Am J Health Syst Pharm 2007 64 : 637 643.
9. Ruijgrok EJ, Vulto AG, Van Etten EW. Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats. J Pharm Pharmacol 2000 52 : 619 627.
10. Schwartz S, Behre G, Heinemann V, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999 93 : 3654 3661.
11. Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin-B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia. Randomized placebo-controlled trial. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2006, M1308-c.
12. Clemons KV, Stevens DA. The contribution of animal models of aspergillosis to understanding pathogenesis, therapy and virulence. Med Mycol 2005 43 (Suppl 1) : S101 110.
13. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003 326 : 219.
14. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003 327 : 557 560.
15. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000 56 : 455 463.
16. Ruijgrok EJ, Fens MH, Bakker-Woudenberg IA, van Etten EW, Vulto AG. Nebulization of four commercially available amphotericin B formulations in persistently granulocytopenic rats with invasive pulmonary aspergillosis: evidence for long-term biological activity. J Pharm Pharmcol 2005 57 : 1289 1295.
17. Cicogna CE, White MH, Bernard EM, et al. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1997 41 : 259 261.
18. Allen SD, Sorensen KN, Nejdl MJ, Durrant C, Proffit RT. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother 1994 34 : 1001 1013.
19. Niki Y, Bernard EM, Edwards FF, Schmitt HJ, Yu B, Armstrong D. Model of recurrent pulmonary aspergillosis in rats. J Clin Microbiol 1991 29 : 1317 1322.
20. Schmitt HJ, Bernard EM, Häuser M, Armstrong D. Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1988 32 : 1676 1679.
21. Ruijgrok EJ, Fens MH, Bakker-Woudenberg IA, van Etten EW, Vulto AG. Nebulized amphotericin B in rats with severe invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006 50 : 1852 1854.
22. Ruijgrok EJ, Vulto AG, Van Etten EW. Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severe immunocompromised rats. J Antimicrob Chemother 2001 48 : 89 95.
23. Gavaldà J, Martín MT, López P, et al. Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis. Antimicrob Agents Chemother 2005 49 : 3028 3030.
24. Olson JA, Adler-Moore JP, Schwartz J, Jensen GM, Proffit RT. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob Agents Chemother 2006 50 : 2122 2131.
25. Lewis RE, Chamilos G, Prince RA, Kontoyiannis DP. Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice. Antimicrob Agents Chemother 2007 51 : 1078 1081.
26. Minsker OB, Moskovskaia MA, Plakhotnaia GA. Treatment of patients with pulmonary aspergillosis by means of inhalation of amphotericin B aerosols. Probl Tuberk 1983 68 69.
27. Singh J, Rimek D, Kappe R. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B. Mycoses 2006 49 : 96 103.
28. Caston JJ, Linares MJ, Gallego C, et al. Risk factors for pulmonary Aspergillus terreus infection in patients with positive culture for filamentous fungi. Chest 2007 131 : 230 236.
29. Drew RH, Dodds Ashley E, Benjamin DK Jr., Duane Davis R, Palmer SM, Perfect JR. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004 77 : 232 237.